SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-067700
Filing Date
2024-08-12
Accepted
2024-08-12 16:26:43
Documents
57
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0210767-10q_virpax.htm   iXBRL 10-Q 661864
2 CERTIFICATION ea021076701ex31-1_virpax.htm EX-31.1 7248
3 CERTIFICATION ea021076701ex31-2_virpax.htm EX-31.2 7257
4 CERTIFICATION ea021076701ex32-1_virpax.htm EX-32.1 3294
5 CERTIFICATION ea021076701ex32-2_virpax.htm EX-32.2 3278
  Complete submission text file 0001213900-24-067700.txt   3879799

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE vrpx-20240630.xsd EX-101.SCH 42660
7 XBRL CALCULATION FILE vrpx-20240630_cal.xml EX-101.CAL 20993
8 XBRL DEFINITION FILE vrpx-20240630_def.xml EX-101.DEF 198330
9 XBRL LABEL FILE vrpx-20240630_lab.xml EX-101.LAB 345173
10 XBRL PRESENTATION FILE vrpx-20240630_pre.xml EX-101.PRE 187813
60 EXTRACTED XBRL INSTANCE DOCUMENT ea0210767-10q_virpax_htm.xml XML 338042
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40064 | Film No.: 241197146
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)